Crossmark

Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes

Crossref DOI link: https://doi.org/10.1016/j.medcli.2025.107019

Published Print: 2025-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pérez-Velasco, Miguel A.

Bernal-López, Maria-Rosa

Trenas, Alicia

Ricci, Michele

López-Carmona, María-Dolores

García de Lucas, María-Dolores

Gómez-Huelgas, Ricardo

Pérez-Belmonte, Luis M.
Funding

Funding for this research was provided by:

CIBERCV

Department of Internal Medicine, University of Utah

European Regional Development Fund
License Information

Text and Data Mining valid from 2025-09-01

Text and Data Mining valid from 2025-09-01

stm-asf valid from 2025-09-01

stm-asf valid from 2025-09-01

stm-asf valid from 2025-09-01

stm-asf valid from 2025-09-01

stm-asf valid from 2025-09-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2025.107019

Content Type: article

Copyright: © 2025 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.